Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 35Carcinoma, Hepatocellular 17Neoplasm Metastasis 15Prostatic Neoplasms 13Neoplasms 9Neuroendocrine Tumors 7Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 6Brain Neoplasms 6Sarcoma, Ewing 5Sarcoma 5Osteosarcoma 5Kidney Neoplasms 5Colorectal Neoplasms 5Carcinoma, Transitional Cell 5Recurrence 4Pancreatic Neoplasms 4Multiple Myeloma 4Clear-cell metastatic renal cell carcinoma 4Urinary Bladder Neoplasms 3Lung Neoplasms 3Carcinoid Tumor 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Thyroid Diseases 2Pheochromocytoma 2Paraganglioma 2Neurofibroma, Plexiform 2Melanoma 2

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Recurrence × cabozantinib × Clear all
NCT04204850 2025-12-03

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

University Health Network, Toronto

Phase 2 Recruiting
20 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

NCT06156410 2025-11-14

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Children's Hospital of Philadelphia

Phase 1 Recruiting
30 enrolled
Sarcoma

Recurrence, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT01588821 2020-09-29

Cabozantinib in Advanced Solid Malignancies

Massachusetts General Hospital

Phase 2 Completed
37 enrolled 10 charts
GenitourinaryThoracic

Lung Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Recurrence

NCT01866293 2017-08-30

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
11 enrolled 12 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡